Trial reportPloS one2015
Staphylococcus aureus Bloodstream Infection and Endocarditis--A Prospective Cohort Study.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05522764 (Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity), which is not on this map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Who cites it
55 citing papers in PubMed.
- Epidemiology of bloodstream infections and infective endocarditis: new insights on typical species and echocardiography screening.Open heart · 2026Article
- Susceptibility ofAntibiotics (Basel, Switzerland) · 2026Article
- Genetic determinants of Staphylococcus aureus adhesion shape virulence trade-offs in bacteremia.Nature communications · 2026Article
- BACT-URIE: A Novel Score Integrating Bacteriuria to Predict Infective Endocarditis in Patients WithOpen forum infectious diseases · 2026Article
- In Vivo Emergence of Oxacillin Resistance in mecA-Negative MSSA Endocarditis With Metastatic Infection.Clinical case reports · 2026Article
- Systematic identification of bacterial factors driving Staphylococcus aureus intracellular lifestyle in non-professional phagocytes.Nature communications · 2025Article
- Clinical and laboratory predictors of mortality in Staphylococcus aureus bacteremia.Scientific reports · 2025Article
- Acquisition of daptomycin resistance in patients results in decreased virulence inInfection and immunity · 2025Article
- Infective endocarditis in a Finnish tertiary care hospital: from etiology to embolic events.Annals of medicine · 2024Article
- Current management ofFujita medical journal · 2024Article
- The Utility of Risk Factors to Define Complicated Staphylococcus aureus Bacteremia in a Setting With Low Methicillin-Resistant S. aureus Prevalence.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- RlmQ: a newly discovered rRNA modification enzyme bridging RNA modification and virulence traits inRNA (New York, N.Y.) · 2024Article
- Infective Endocarditis and Antithrombotic Therapy.Cardiology · 2024Review
- Risk of endocarditis among patients with coagulase-negative Staphylococcus bacteremia.Scientific reports · 2023Article
- Positive Impact of [18F]FDG-PET/CT on Mortality in Patients With Staphylococcus aureus Bacteremia Explained by Immortal Time Bias.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Multicenter Retrospective Study of Vascular Infections and Endocarditis Caused by Campylobacter spp., France.Emerging infectious diseases · 2023Review
- All Staphylococcus aureus bacteraemia-inducing strains can cause infective endocarditis: Results of GWAS and experimental animal studies.The Journal of infection · 2023Article
- Neutrophils Protect AgainstArteriosclerosis, thrombosis, and vascular biology · 2023Article
- Article
- Prevalence and Mortality of Infective Endocarditis in Community-Acquired and Healthcare-AssociatedOpen forum infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo update the epidemiology of S. aureus bloodstream infection (SAB) in a high-income country and its link with infective endocarditis (IE).
methodsAll consecutive adult patients with incident SAB (n = 2008) were prospectively enrolled between 2009 and 2011 in 8 university hospitals in France.
resultsSAB was nosocomial in 54%, non-nosocomial healthcare related in 18% and community-acquired in 26%. Methicillin resistance was present in 19% of isolates. SAB Incidence of nosocomial SAB was 0.159/1000 patients-days of hospitalization (95% confidence interval [CI] 0.111-0.219). A deep focus of infection was detected in 37%, the two most frequent were IE (11%) and pneumonia (8%). The higher rates of IE were observed in injecting drug users (IE: 38%) and patients with prosthetic (IE: 33%) or native valve disease (IE: 20%) but 40% of IE occurred in patients without heart disease nor injecting drug use. IE was more frequent in case of community-acquired (IE: 21%, adjusted odds-ratio (aOR) = 2.9, CI = 2.0-4.3) or non-nosocomial healthcare-related SAB (IE: 12%, aOR = 2.3, CI = 1.4-3.5). S. aureus meningitis (IE: 59%), persistent bacteremia at 48 hours (IE: 25%) and C-reactive protein > 190 mg/L (IE: 15%) were also independently associated with IE. Criteria for severe sepsis or septic shock were met in 30% of SAB without IE (overall in hospital mortality rate 24%) and in 51% of IE (overall in hospital mortality rate 35%).
conclusionSAB is still a severe disease, mostly related to healthcare in a high-income country. IE is the most frequent complication and occurs frequently in patients without known predisposing conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.